Literature DB >> 28337871

Cytokine modulation in patients with idiopathic pulmonary fibrosis undergoing treatment with steroids, immunosuppressants, and IFN-γ 1b.

S Marinari1, V De Iuliis2, V Dadorante3, S Colella1, A Marino2, A Nunziata2, V Flati4, M Caruso2, A Pennelli3, F De Benedetto5, S Matera2, S Capodifoglio2, S Martinotti2, S Caputi2, E Toniato2.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of unknown etiology and pathogenic mechanisms. From an etiopathogenic point of view, alveolar macrophages play a key role in accumulation of fibroblasts and deposition of collagen and extracellular matrix by releasing specific cytokines and inflammatory mediators. IPF seems to be also associated with circulating fibrocytes, which might be involved with an abnormal pulmonary vascular repair and remodeling. Based on its hypothesized pathologic mechanisms, anti-inflammatory, anti-fibrotic and immunosuppressive therapies are often used. For these reasons, Interferon-g (IFN-g) has been used to exploit its activity on macrophages and fibroblasts. The aim of this study was to investigate the response to corticosteroids and/or IFN-g 1b treatments based on pulmonary function tests and on inflammatory cytokine patterns of expression on bronchoalveolar lavage (BAL), at baseline and during and after the therapies. Unlike previous studies, we analyzed a period of therapy longer than 1 year. Our results demonstrated the effectiveness of IFN-γ in a group of IPF patients in whom the treatment was prolonged for over a year. These data suggest a positive role of IFN-γ; treatment in patients in the initial stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28337871

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  2 in total

Review 1.  Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells.

Authors:  Pio Conti; Francesco Carinci; Gianfranco Lessiani; Enrico Spinas; Spyridon K Kritas; Gianpaolo Ronconi; Alessandro Caraffa; Theoharis C Theoharides
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

Review 2.  Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37.

Authors:  P Conti; Al Caraffa; F Mastrangelo; L Tettamanti; G Ronconi; I Frydas; S K Kritas; T C Theoharides
Journal:  Cell Prolif       Date:  2018-07-30       Impact factor: 8.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.